Precision BioSciences
| General Information | |
| Business: |
We are a genome editing company dedicated to improving life through our groundbreaking proprietary genome editing platform, “ARCUS.” We leverage ARCUS in the development of our product candidates, which are designed to treat human diseases and create healthy and sustainable food and agricultural solutions. We believe the versatility and breadth of ARCUS support our ability to develop products across the spectrum of biotechnology. |
| Industry: | BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) |
| Employees: | 127 |
| Founded: | 2006 |
| Contact Information | |
| Address | 302 East Pettigrew St., Suite A-100, Durham, NC 27701, US |
| Phone Number | (919) 314-5512 |
| Web Address | http://www.precisionbiosciences.com |
| View Prospectus: | Precision BioSciences |
| Financial Information | |
| Market Cap | $784.5mil |
| Revenues | $10.9 mil (last 12 months) |
| Net Income | $-46.0 mil (last 12 months) |
| IPO Profile | |
| Symbol | DTIL |
| Exchange | NASDAQ |
| Shares (millions): | 7.9 |
| Price range | $16.00 - $16.00 |
| Est. $ Volume | $126.4 mil |
| Manager / Joint Managers | J.P. Morgan/ Goldman Sachs/ Jefferies/ Barclays |
| CO-Managers | - |
| Expected To Trade: | 3/28/2019 |
| Status: | Priced |
| Quiet Period Expiration Date: | Available only to Subscribers |
| Lock-Up Period Expiration Date: | Available only to Subscribers |
| SCOOP Rating | Available only to Subscribers |
| Rating Change | Available only to Subscribers |